Drug Trial Radar · NCT04787744
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
378
Actual
Start
Jul 1, 2021
Primary completion
Oct 2, 2026
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Mar 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Conditions
- Prostate Cancer
- Oligometastasis
- Oligorecurrence
- Recurrent Prostate Cancer
- Metastatic Prostate Cancer
- De Novo Prostate Cancer
Interventions
PET-directed Local Therapy using SurgeryProcedure
Surgery will be used to treat metastases.
PET-directed Local Therapy using RadiationRadiation
Radiation therapy will be used to treat metastases. Radiation options include: 1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions 2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran.
Salvage Local Therapy for locally recurrent diseaseOther
For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
Goserelin, Histrelin, Leuprolide & TriptorelinDrug
Androgen deprivation therapy (ADT) using an LHRH agonist
ADT + Nilutamide, Flutamide, & BicalutamideDrug
ADT adding anti-androgen therapy to an LHRH agonist
Degarelix & RelugolixDrug
ADT using an LHRH Antagonist.
ADT + Docetaxel +/- prednisoneDrug
Enhanced SST using chemohormonal therapy
ADT + Abiraterone + PrednisoneDrug
Enhanced SST using Abiraterone + Prednisone
ADT + Abiraterone + MethylprednisoloneDrug
Enhanced SST using Abiraterone + Methylprednisolone
ADT + ApalutamideDrug
Enhanced SST using ADT + Apalutamide
ADT + EnzalutamideDrug
Enhanced SST using ADT + Enzalutamide
Prostate-directed Radiation for De novo oligometastatic prostate cancerRadiation
Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites. Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions. Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Castration-resistant prostate cancer-free survival (CRPC-free survival)Time frame: 4 years
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
VA Long Beach Healthcare System, Long Beach, CA
Long Beach, California
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California
Washington DC VA Medical Center, Washington, DC
Washington D.C., District of Columbia
Bay Pines VA Healthcare System, Pay Pines, FL
Bay Pines, Florida
Edward Hines Jr. VA Hospital, Hines, IL
Hines, Illinois
Richard L. Roudebush VA Medical Center, Indianapolis, IN
Indianapolis, Indiana
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Baltimore, Maryland
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, Michigan
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota
Kansas City VA Medical Center, Kansas City, MO
Kansas City, Missouri
East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ
East Orange, New Jersey
VA NY Harbor Healthcare System, New York, NY
New York, New York
Durham VA Medical Center, Durham, NC
Durham, North Carolina
Louis Stokes VA Medical Center, Cleveland, OH
Cleveland, Ohio
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas
Hunter Holmes McGuire VA Medical Center, Richmond, VA
Richmond, Virginia
William S. Middleton Memorial Veterans Hospital, Madison, WI
Madison, Wisconsin
Clement J. Zablocki VA Medical Center, Milwaukee, WI
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.